MedTrace Logo

A Study of TIL in Advanced Solid Tumors (DFGD)

NCT06488950 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-16

No results posted yet for this study

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

  • Advanced Solid Tumor
  • Tumor Infiltrating Lymphocytes
  • Treatment Side Effects
  • Effects of Immunotherapy

Interventions

BIOLOGICAL

GC203 TIL(gene-edited TIL) or autologous TILs

the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    collaborator OTHER

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Principal Investigators

  • Qian Zhang · Eastern Hepatobiliary Surgery Hospital

  • Wenlong Yu · Eastern Hepatobiliary Surgery Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488950 on ClinicalTrials.gov